Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan - Seite 2

ARAZLO is produced by Bausch Health, Canada for Canadian patients and for export at the company's manufacturing facility in Laval, Quebec.

About Acne Vulgaris
Acne vulgaris ("vulgaris" means "common") is the most common skin problem seen by doctors in Canada. It occurs when the pores of the skin become plugged with oil and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Acne affects about 5.6 million Canadians, or nearly 20 per cent of the population and causes emotional distress and can cause permanent scarring¹ or pigmentation changes.⁴ Acne affects about 90 per cent of adolescents and about 25 per cent of teens will still have acne at age 25.³

About ARAZLO
ARAZLO tazarotene lotion, 0.045% w/w is a topical prescription indicated for the topical treatment of acne vulgaris. ARAZLO can be used on affected areas in patients 12 years and older and on affected areas of the face only of those aged 10 and 11. The safety and efficacy of ARAZLO in children below the age of 10 years has not been established.¹

About Bausch Health

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, healthcare professionals, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

The Bausch Health Canadian prescription treatment portfolio is focused on dermatology, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada: in Laval, Quebec, and Steinbach, Manitoba. More information can be found at the Company's website at www.bauschhealth.ca.

REFERENCES

1. ^PrARAZLO (Tazarotene Lotion, 0.045% w/w) Product Monograph, July 7, 2021.

2. "Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems." Pharmaceutics. Gemma Latter et al, October 2019, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835300/, accessed Nov. 1, 2022.